GW Pharmaceuticals Plc (GWPH)

187.21
3.21 1.74
NASDAQ : Health Technology
Prev Close 184.00
Open 184.36
Day Low/High 181.27 / 188.76
52 Wk Low/High 90.14 / 196.00
Volume 357.65K
Avg Volume 473.10K
Exchange NASDAQ
Shares Outstanding 30.72M
Market Cap 5.65B
EPS -10.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Jim Cramer's 'Mad Money' Recap: Clear the Slate for Earnings Season

Jim Cramer's 'Mad Money' Recap: Clear the Slate for Earnings Season

Starting next week, stocks will only move higher if companies can beat on the top and bottom lines and raise guidance for the rest of the year, Cramer said.

Cramer: Can't Take the Heat? Get Out of Specs

Cramer: Can't Take the Heat? Get Out of Specs

Accept the risk you're taking on and, above all, be a grown-up about it.

Can't Take the Heat? Get Out of Specs

Accept the risk you're taking on and, above all, be a grown-up about it.

'Mad Money' Lightning Round: American Airlines Delivers

'Mad Money' Lightning Round: American Airlines Delivers

Cramer is avoiding Annaly Capital, warns GW Pharmaceuticals could have ups and down and likes Ensco over Transocean.

Jim Cramer's 'Mad Money' Recap: Buy, Don't Sell, on European Weakness

Jim Cramer's 'Mad Money' Recap: Buy, Don't Sell, on European Weakness

It's not 2008 anymore and one Portugal bank's problems is no reason to panic, Cramer says.

A No-Drama Market

Not much reason to sell right now.

GW Pharma Rises After Analyst Sees Promise in Marijuana-Derived Epilepsy Drug

GW Pharma Rises After Analyst Sees Promise in Marijuana-Derived Epilepsy Drug

Shares of GW Pharmaceuticals (GWPH) are climbing after research firm Piper Jaffray sharply raised its price target on the stock after speaking with epilepsy specialists.

Jim Cramer's Stop Trading: 'Amazed' by GW Pharmaceuticals

Jim Cramer's Stop Trading: 'Amazed' by GW Pharmaceuticals

TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, says GW Pharmaceuticals' epilepsy treatment could be used for other diseases too.

Why GW Pharmaceuticals (GWPH) Stock Is Rising Today

Why GW Pharmaceuticals (GWPH) Stock Is Rising Today

GW Pharmaceuticals (GWPH) shares are up after having its price target increased to $147 by analysts at Piper Jaffray (PJC).

Why I'm Not High on GW Pharma

Forget marijuana, there's a more basic reason to be bearish.

Jim Cramer's Top Stock Picks: MON GIS PPG EOG UNP GWPH STZ

Jim Cramer's Top Stock Picks: MON GIS PPG EOG UNP GWPH STZ

Cramer is high on GW Pharmaceuticals and will be watching for Monsanto's and General Mills' earnings next week.

'Fast Money' Recap: Muddling Along to Another All-Time High

'Fast Money' Recap: Muddling Along to Another All-Time High

The trading panel discussed the health of the U.S. consumer and which stocks to avoid for the summer.

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer will be watching Chinese economic data, company earnings and other things to get investors excited next week.

Jim Cramer's Stop Trading: GW Pharmaceuticals Is 'A Winner'

Jim Cramer's Stop Trading: GW Pharmaceuticals Is 'A Winner'

TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, takes a look at GW Pharmaceuticals' secondary offering and outlines the bull case for the company.

Jim Cramer's Stop Trading: Buy GW Pharmaceuticals, Not ConAgra Foods

Jim Cramer's Stop Trading: Buy GW Pharmaceuticals, Not ConAgra Foods

TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, says investors should buy GW Pharmaceuticals on its secondary offering. He did not like ConAgra Foods earnings results.

'Fast Money' Recap: Waiting on the Fed

'Fast Money' Recap: Waiting on the Fed

The trading panel discussed what one perceived hawkish comment from the central bank could do to stocks and bonds.

Why GW Pharmaceuticals (GWPH) Stock Hit a One-Year High Today

Why GW Pharmaceuticals (GWPH) Stock Hit a One-Year High Today

GW Pharmaceuticals (GWPH) surged to a 52-week high of $89.48 on Tuesday after the British biotech company reported positive safety and efficacy data from its epilepsy treatment drug Epidiolex.

Jim Cramer's Stop Trading: GW Pharmaceuticals Is for Real

Jim Cramer's Stop Trading: GW Pharmaceuticals Is for Real

TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, says GW Pharmaceuticals is the real deal when it comes to medical marijuana, and he is taking a look at its latest report that backs that claim up.

How the U.S. Government Makes Money on Cannabis

How the U.S. Government Makes Money on Cannabis

The U.S. government holds a patent on cannabinoids and has collected money for licensing the patent. It could eventually collect thousands of dollars in royalties.

3 Stocks Spiking on Big Volume

3 Stocks Spiking on Big Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

'Mad Money' Lightning Round: Avoid Cliffs Natural Resources

'Mad Money' Lightning Round: Avoid Cliffs Natural Resources

Cramer likes Sysco and GW Pharmaceuticals but isn't crazy about Bank of America or Amazon.

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Next week Cramer will be watching for positive data out of China and company earnings in the U.S.

Jim Cramer's Stop Trading: GW Pharmaceuticals Is Going Higher

Jim Cramer's Stop Trading: GW Pharmaceuticals Is Going Higher

TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, continues to like GW Pharmaceuticals to the upside.

'Mad Money' Lightning Round: Aetna Is Terrific

'Mad Money' Lightning Round: Aetna Is Terrific

Cramer says GW Pharmaceuticals is good for the long term and sees Popeyes Louisiana Kitchen going higher.

Jim Cramer's 'Mad Money' Recap: A World Upside Down

Jim Cramer's 'Mad Money' Recap: A World Upside Down

Sometimes this wacky market has a mind all of its own, Cramer says.